CA2302808C - 50 proteines secretees d'origine humaine - Google Patents

50 proteines secretees d'origine humaine Download PDF

Info

Publication number
CA2302808C
CA2302808C CA2302808A CA2302808A CA2302808C CA 2302808 C CA2302808 C CA 2302808C CA 2302808 A CA2302808 A CA 2302808A CA 2302808 A CA2302808 A CA 2302808A CA 2302808 C CA2302808 C CA 2302808C
Authority
CA
Canada
Prior art keywords
polypeptide
seq
gene
sequence
polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2302808A
Other languages
English (en)
Other versions
CA2302808A1 (fr
Inventor
Paul A. Moore
Steven M. Ruben
David W. Lafleur
Yanggu Shi
Craig A. Rosen
Henrik S. Olsen
Reinhard Ebner
Laurie A. Brewer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Genome Sciences Inc
Original Assignee
Human Genome Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc filed Critical Human Genome Sciences Inc
Publication of CA2302808A1 publication Critical patent/CA2302808A1/fr
Application granted granted Critical
Publication of CA2302808C publication Critical patent/CA2302808C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La présente invention se rapporte à de nouvelles protéines sécrétées d'origine humaine et à des acides nucléiques isolés contenant les régions codantes des gènes codant ces protéines. L'invention se rapporte également à des vecteurs, à des cellules hôtes, à des anticorps et à des procédés de recombinaison permettant de produire des protéines sécrétées humaines. Elle se rapporte en outre à des procédés diagnostiques et thérapeutiques conçus pour diagnostiquer et traiter des troubles liés à ces nouvelles protéines sécrétées humaines.
CA2302808A 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine Expired - Fee Related CA2302808C (fr)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US5766997P 1997-09-05 1997-09-05
US5762697P 1997-09-05 1997-09-05
US5766397P 1997-09-05 1997-09-05
US60/057,669 1997-09-05
US60/057,626 1997-09-05
US60/057,663 1997-09-05
US5897497P 1997-09-12 1997-09-12
US5866797P 1997-09-12 1997-09-12
US5897397P 1997-09-12 1997-09-12
US5866697P 1997-09-12 1997-09-12
US60/058,667 1997-09-12
US60/058,666 1997-09-12
US60/058,974 1997-09-12
US60/058,973 1997-09-12
PCT/US1998/018360 WO1999011293A1 (fr) 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine

Publications (2)

Publication Number Publication Date
CA2302808A1 CA2302808A1 (fr) 1999-03-11
CA2302808C true CA2302808C (fr) 2010-05-18

Family

ID=27568129

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2302808A Expired - Fee Related CA2302808C (fr) 1997-09-05 1998-09-03 50 proteines secretees d'origine humaine

Country Status (5)

Country Link
EP (1) EP1019091A4 (fr)
JP (2) JP2001514024A (fr)
AU (1) AU9130498A (fr)
CA (1) CA2302808C (fr)
WO (1) WO1999011293A1 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002591A1 (en) 1997-09-05 2004-01-01 Human Genome Sciences, Inc. 50 human secreted proteins
WO1999055868A2 (fr) * 1998-04-24 1999-11-04 Genentech, Inc. Proteines fizz
US6503730B1 (en) 1997-06-19 2003-01-07 Schering Corporation Nucleic acids encoding a cysteine rich protein
ATE525390T1 (de) * 1999-04-27 2011-10-15 Univ Pennsylvania Verwendung von resistin spezifischen antikörpern in der behandlung von diabetes
EP1255831A2 (fr) 2000-01-19 2002-11-13 The University Of Virginia Patent Foundation Proteines specifiques du sperme
WO2001060859A1 (fr) * 2000-02-21 2001-08-23 Kureha Chemical Industry Co., Ltd. Nouvelles proteines et nouveaux genes codant ces proteines
EP1138765A1 (fr) * 2000-03-27 2001-10-04 Leadd B.V. Protéines AAP-5 et AAP-6 associées à l'apoptine
EP1138768A3 (fr) * 2000-03-27 2002-08-07 Leadd B.V. Protéine AAP-5 liant l' apoptine
ES2296829T3 (es) * 2000-11-06 2008-05-01 Cancer Research Technology Limited Imaginologia, diagnostico y tratamiento de la enfermedad.
WO2002057420A2 (fr) * 2001-01-18 2002-07-25 Human Genome Sciences, Inc. 50 proteines secretees humaines
EP1399460A4 (fr) * 2001-04-27 2005-04-13 Sunnybrook & Women S College H Genes associes au cancer du sein et utilisations correspondantes
US7109302B1 (en) 2002-04-01 2006-09-19 Human Genome Sciences, Inc. Antibodies that specifically bind to GMAD
ATE462727T1 (de) 2002-11-20 2010-04-15 Cancer Rec Tech Ltd An menschliches roundabout bindende antikörper, polypeptide und ihre verwendung zur hemmung der angiogenese
MX2009008430A (es) 2007-02-09 2009-10-28 Genentech Inc Anticuerpos anti-robo4 y sus usos.
US20110038885A1 (en) * 2007-07-26 2011-02-17 Zheng Xin Dong Chemokine analogs
MX393006B (es) 2017-06-02 2025-03-24 Fujifilm Toyama Chemical Co Ltd Agente para reducir la cantidad de proteina beta amiloide.
US11541033B2 (en) 2017-06-02 2023-01-03 Fujifilm Toyama Chemical Co., Ltd. Agent for preventing or treating Alzheimer's disease
KR20190137936A (ko) 2017-06-02 2019-12-11 후지필름 도야마 케미컬 가부시키가이샤 뇌 위축 예방 또는 치료제
CA3067455C (fr) 2017-06-02 2021-11-23 Fujifilm Toyama Chemical Co., Ltd. Agent de prevention ou de traitement de l'ataxie spinocerebelleuse
JP7227914B2 (ja) * 2017-10-30 2023-02-22 富士フイルム富山化学株式会社 エモパミル結合タンパク質結合剤およびその利用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263865T3 (es) * 1998-03-25 2006-12-16 Genentech, Inc. Homologo humano de neurotrimina.

Also Published As

Publication number Publication date
EP1019091A4 (fr) 2005-05-11
CA2302808A1 (fr) 1999-03-11
AU9130498A (en) 1999-03-22
JP2001514024A (ja) 2001-09-11
EP1019091A1 (fr) 2000-07-19
WO1999011293A1 (fr) 1999-03-11
JP2009131263A (ja) 2009-06-18

Similar Documents

Publication Publication Date Title
CA2302808C (fr) 50 proteines secretees d'origine humaine
US6531447B1 (en) Secreted protein HEMCM42
US20030045459A1 (en) 67 Human secreted proteins
CA2323776C (fr) Analogue de chaine gamma commune de recepteur de cytokine
US6525174B1 (en) Precerebellin-like protein
WO1998045712A2 (fr) 20 proteines humaines secretees
US20040002066A1 (en) 36 human secreted proteins
US20040014954A9 (en) Human protein hfxjw48
US6433139B1 (en) Secreted protein HPEAD48
US20040024192A1 (en) 19 human secreted proteins
US20030004324A1 (en) 31 human secreted proteins
US20030105297A1 (en) Secreted protein HEMCM42
US6806351B2 (en) Secreted protein HBJFE12
US6410709B1 (en) Cornichon-like protein
US20030144492A1 (en) 101 human secreted proteins
CA2298852A1 (fr) 83 proteines humaines secretees
US20030176681A1 (en) 148 human secreted proteins
US20040063128A1 (en) 20 Human secreted proteins
US6365369B1 (en) Prostate specific secreted protein
CA2319097A1 (fr) Molecule d'activation lymphocytaire secretee enrichie par les cellules dendritiques
US20030166906A1 (en) 50 human secreted proteins
US20040185440A9 (en) 125 human secreted proteins
EP1445316A1 (fr) Nouvelle protéine secretée

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed